PPARα酸化调节了结直肠瘤免疫逃脱的过程
Qian Gou1, Xiaoqing Tian1, Chen Dong1
1School of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu Province, The People's Republic of China.
The Journal of biological chemistry
|June 6, 2024
概括
PPARα的损失通过增加PD-L1表达来促进结直肠癌的免疫逃生. 用抑制剂和激动剂向ERK-PPARα通路可能会增强抗瘤免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 癌细胞中的高PD-L1水平驱动免疫逃脱并阻碍免疫治疗.
- PD-L1基因转录抑制的机制在很大程度上是未知的.
研究的目的:
- 调查氧酶增殖器激活受体α (PPARα) 在结直肠瘤免疫逃生中的作用.
- 阐明PPARα调节PD-L1表达的分子机制.
主要方法:
- 对PPARα在结直肠瘤免疫逃生中的作用的分析.
- 对PPARα与PD-L1促进体结合的研究.
- 对PPARα激动剂和ERK抑制剂对PD-L1表达和T细胞活性的影响的评估.
主要成果:
- 发现PPARα的损失可以促进结直肠瘤的免疫逃生.
- PPARα直接与PD-L1促进体结合,抑制其转录.
- 由ERK诱导的PPARα酸化阻断了其抑制功能,增加了PD-L1水平.
- 使用ERK抑制剂和PPARα激动剂的联合治疗显著减少了瘤免疫逃逸.
结论:
- 该ERK-PPARα通路在调节PD-L1基因转录中起着至关重要的作用.
- 这种途径的抑制代表了一种潜在的治疗策略,以克服结直肠癌中的瘤免疫逃脱.
更多相关视频
06:19Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
Published on: July 18, 2017
10.0K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.7K
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
